Merck, Sharp & Dohme Ltd
2004 - Oct 2008 Marketing Manager
Merck, Sharp and Dohme (MSD), Hoddesdon, Hertfordshire
• Developed optimal position for INVANZ in the UK market.
2004: 225% of plan - most profitable performance (all countries)
2005: 156% of plan - most profitable performance (all countries)
2006:26% growth 2006/2005 (most profitable)
2007:37% growth 2007/2006 (most profitable)
Jun 1993 - 2004 Marketing Manager
·Prepared draft launch plan for SINGULAIR. Recruited and appointed PM for launch of SINGULAIR.
·Launched AGGRASTAT successfully in July 1999.
·National audit of unstable angina management completed in 56 UK hospitals in collaboration with the Royal Brompton Hospital (PRAIS UK registry).
·NICE provided positive guidance on role of IIbIIIa antagonists in July 2000 following submission of dossier in April 2000.
·Arranged the first ever joint meeting between MSD and both British Cardiology Society (BCS) and the European equivalent.
·Established effective working relations with HIV KOLs and BHIVA.
·Worked with UK microbiologists and BSAC members to define medical need for INVANZ in the UK. Prepared launch plan.
Jul 1991 - Jun 1993Manager: Healthcare Group
Jul 1990 - Jun 1991Healthcare Relations Manager
Jul 1989 - Jun 1990Manager - Sales Training MSD UK
Jul 1987 - Jun 1989District Manager
Jul 1985 - Jun 1987Product Manager: Hepatitis B Vaccine (HBVax) and Pepcid
1984–1983Sales Training Specialist
1982 - 1983Market Research Analyst (development)
1982-1981Assistant to Sales Manager
1979-1981Sales Representative MSD UK